Phase 3 ARB Clinical Trials

2 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–2 of 2 trials

Recruiting

Phase 3

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC

Shanghai JMT-Bio Inc.516 enrolled1 locationNCT06735391

Recruiting

Phase 3

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

CisplatinCarboplatinNPC

Nanfang Hospital, Southern Medical University482 enrolled1 locationNCT03919552